Past Issues: Ophthalmic disease
- 2009 Ophthalmic disease
- 2008 Ophthalmic disease
- January 2009 Ophthalmic disease
- February 2009 Ophthalmic disease
- March 2009 Ophthalmic disease
- April 2009 Ophthalmic disease
- May 2009 Ophthalmic disease
- June 2009 Ophthalmic disease
- August 2009 Ophthalmic disease
- September 2009 Ophthalmic disease
- October 2009 Ophthalmic disease
- November 2009 Ophthalmic disease
June 2009
Targets and Mechanisms
Seeing CNV sooner
by Michael J. Haas, Senior Writer
Published online June 25 2009; doi:10.1038/scibx.2009.995
A multinational research team suggests that noninvasive imaging of CCR3 could help detect incipient wet age-related macular degeneration, making earlier therapeutic intervention possible. The researchers also suggest that CCR3 inhibition could be used to augment treatment with VEGF-A inhibitors.
Full text - Seeing CNV sooner | PDF (174 KB) - Seeing CNV sooner
Distillery: Therapeutics
CC chemokine receptor 3 (CCR3); eotaxin-1 (CCL11); eotaxin-2 (CCL24); eotaxin-3 (CCL26)
Published online June 18 2009; doi:10.1038/scibx.2009.983
Studies in human tissues and in mice suggest that targeting CCR3 or its ligands could help treat AMD.
Summary - CC chemokine receptor 3 (CCR3); eotaxin-1 (CCL11); eotaxin-2 (CCL24); eotaxin-3 (CCL26) | PDF (113 KB) - CC chemokine receptor 3 (CCR3); eotaxin-1 (CCL11); eotaxin-2 (CCL24); eotaxin-3 (CCL26)
Distillery: Therapeutics
Not applicable
Published online June 11 2009; doi:10.1038/scibx.2009.952
In vitro and mouse studies suggest that cortistatin A analogs could help block angiogenesis to treat wet age-related macular degeneration (AMD).
